RecruitingNot ApplicableNCT07496021

Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

Sponsor

CKD Bio Corporation

Enrollment

60 participants

Start Date

Feb 23, 2026

Study Type

INTERVENTIONAL

Conditions

Early Alzheimers Disease

Summary

Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

Eligibility

Min Age: 55 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called L. lactis CKDB001 and a drug called Placebo for people with early alzheimers disease. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 55 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGL. lactis CKDB001

Oral Capsule

DRUGPlacebo

Oral Capsule

Locations(2)

Yonsei University Yongin Severance Hospital

Gyeonggi-do, South Korea

Yonsei University Severance Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07496021

Related Trials

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT0670901481 locations